{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:37:39Z","timestamp":1793878659060,"version":"4.7.0"},"reference-count":120,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"paratek","award":["na"],"award-info":[{"award-number":["na"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Oral tetracyclines have been used in clinical practice for over 60 years. Overall, one of the most common indications for use of oral tetracyclines is for treatment of adult outpatients with lower respiratory tract infections, including community-acquired pneumonia (CAP). Despite the longstanding use of oral tetracyclines, practice patterns indicate that they are often considered after other guideline-concordant oral CAP treatment options (namely macrolides, fluoroquinolones, and \u03b2-lactams). However, there are growing resistance or safety concerns with the available oral agents listed for outpatients with CAP in the updated American Thoracic Society (ATS)\/Infectious Diseases Society of America (IDSA) CAP guidelines, especially among patients with comorbidities or notable risk factors for resistant pathogens. Given the need for alternative oral agents to macrolides, fluoroquinolones, and beta-lactams for adult outpatients with CAP, this review summarizes the literature on the use of oral tetracyclines (i.e., doxycycline, minocycline, and omadacycline) for this indication. As part of this review, we described their mechanism of action, common mechanisms of resistance, susceptibility profiles against common CAP pathogens, pharmacokinetics, pharmacodynamics, clinical data, and safety. The intent of the review is to highlight the important considerations when deciding between doxycycline, minocycline, and omadacycline for an adult outpatient with CAP in situations in which use of an oral tetracycline is warranted.<\/jats:p>","DOI":"10.3390\/antibiotics9120905","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T21:25:08Z","timestamp":1607981108000},"page":"905","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class"],"prefix":"10.3390","volume":"9","author":[{"given":"Monique R.","family":"Bidell","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath (Amit) P.","family":"Pai","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline Antibiotics and Resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10096-017-3081-x","article-title":"Similarities and differences between doxycycline and minocycline: Clinical and antimicrobial stewardship considerations","volume":"37","author":"Cunha","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0025-7125(16)30039-6","article-title":"Tetracyclines","volume":"79","author":"Klein","year":"1995","journal-title":"Med. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-198206000-00002","article-title":"Minocycline","volume":"4","author":"Jonas","year":"1982","journal-title":"Ther. Drug Monit."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-198206000-00001","article-title":"Doxycycline","volume":"4","author":"Cunha","year":"1982","journal-title":"Ther. Drug Monit."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","unstructured":"(2019, June 01). Nuzyra (Omadacycline) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf."},{"key":"ref_9","unstructured":"Centers for Disease Control and Prevention (2019, September 08). Active Bacterial Core surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus Pneumoniae, Available online: https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu16.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/430906","article-title":"Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes?","volume":"41","author":"Doern","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijantimicag.2004.12.001","article-title":"Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002\u20132003): Contemporary in vitro activities of amoxicillin\/clavulanate and 15 other antimicrobial agents","volume":"25","author":"Pottumarthy","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3810\/pgm.2008.09.suppl52.279","article-title":"Tracking resistance among bacterial respiratory tract pathogens: Summary of findings of the TRUST Surveillance Initiative, 2001\u20132005","volume":"120","author":"Sahm","year":"2008","journal-title":"Postgrad Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Huband, M.D., Shortridge, D., and Flamm, R.K. (2020). Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02488-19"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0149-2918(03)90021-X","article-title":"Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic\/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents","volume":"25","author":"Peric","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/jac\/dkw226","article-title":"Non-linear absorption pharmacokinetics of amoxicillin: Consequences for dosing regimens and clinical breakpoints","volume":"71","author":"Koch","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/AAC.00736-06","article-title":"Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","unstructured":"Clinical and Laboratory Standards Institute (2017). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [27th ed.]. CLSI Supplement M100."},{"key":"ref_18","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2020, August 01). Amoxicillin. Rationale for the EUCAST Clinical Breakpoints, Version 1.0. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Amoxicillin_rationale_Nov2010_v_1.0.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/1120009X.1990.11739021","article-title":"Impact of antimicrobial agents on human intestinal microflora","volume":"2","author":"Nord","year":"1990","journal-title":"J. Chemother."},{"key":"ref_20","unstructured":"US Food and Drug Administration (2018, September 20). FDA Reinforces Safety Information about Serious Low Blood Sugar Levels and Mental Health Side Effects with Fluoroquinolone Antibiotics; Requires Label Changes, Available online: www.fda.gov\/Drugs\/DrugSafety\/ucm611032.htm."},{"key":"ref_21","unstructured":"European Medicines Agency (EMA\/795349\/2018) (2019, August 12). Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf."},{"key":"ref_22","unstructured":"FDA Drug Safety Communication (2020, August 01). FDA Warns about Increased Risk of Ruptures or Tears in the Aorta Blood Vessel with Fluoroquinolone Antibiotics in Certain Patients, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics."},{"key":"ref_23","unstructured":"FDA Drug Safety Communication (2020, August 01). FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics due to Disabling Side Effects, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/phar.2185","article-title":"Omadacycline Enters the Ring: A New Antimicrobial Contender","volume":"38","author":"Barber","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/jac\/dkv060","article-title":"Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing","volume":"70","author":"Lupien","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.02465-15","article-title":"Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance","volume":"60","author":"Linkevicius","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3389\/fmicb.2018.01058","article-title":"Tetracycline-Inactivating Enzymes","volume":"9","author":"Markley","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ki.1974.52","article-title":"Doxycycline pharmacokinetics in the absence of renal function","volume":"5","author":"Whelton","year":"1974","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/mdr.1998.4.79","article-title":"The molecular mechanisms of tetracycline resistance in the pneumococcus","volume":"4","author":"Widdowson","year":"1998","journal-title":"Microb. Drug Resist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/CMR.00058-15","article-title":"Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: A United States Perspective","volume":"29","author":"Kim","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_33","unstructured":"FDA Drug Safety Communication (2020, August 01). Omadacycline Injection and Oral Products, Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2013.01.023","article-title":"Contemporary tetracycline susceptibility testing: Doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/15412555.2010.510162","article-title":"Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure","volume":"7","author":"Desai","year":"2010","journal-title":"COPD"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0732-8893(02)00540-0","article-title":"Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: Results of the SENTRY Antimicrobial Surveillance Study (2000)","volume":"45","author":"Hoban","year":"2003","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-7-1","article-title":"Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: Update from PROTEKT US Years 1-4","volume":"7","author":"Jenkins","year":"2008","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_38","first-page":"9","article-title":"The Viriato Study: Update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004","volume":"12","author":"Santos","year":"2006","journal-title":"Rev. Port. Pneumol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.diagmicrobio.2004.02.005","article-title":"Doxycycline use for community-acquired pneumonia: Contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999\u20132002)","volume":"49","author":"Jones","year":"2004","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Huband, M.D., Shortridge, D., and Flamm, R.K. (2018). Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02327-17"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/374253","article-title":"Doxycycline sensitivity of S. pneumoniae isolates","volume":"36","author":"Lederman","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Huband, M.D., Rhomberg, P.R., and Flamm, R.K. (2017). Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00018-17"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and Preclinical Review of Omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","article-title":"In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas","volume":"60","author":"Waites","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Waites, K.B., Crabb, D.M., Duffy, L.B., Jensen, J.S., Liu, Y., and Paukner, S. (2017). In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02008-16"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Dubois, J., Dubois, M., and Martel, J.F. (2020). In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01972-19"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","article-title":"Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014)","volume":"90","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-019-00843-4","article-title":"Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics","volume":"59","author":"Rodvold","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_53","unstructured":"(2020, August 01). DORYX\u00ae (Doxycycline Hyclate) Delayed-Release Tablets, 75 mg, 100 mg and 150 mg for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050795s005lbl.pdf."},{"key":"ref_54","unstructured":"(2020, August 01). MINOCIN\u00ae (Minocycline Hydrochloride) Pellet-Filled Capsules, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050649023lbl.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jac\/1.3.323","article-title":"Activity of minocycline and tetracycline against respiratory pathogens related to blood levels","volume":"1","author":"Wood","year":"1975","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.11.3.462","article-title":"Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects","volume":"11","author":"Welling","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00562453","article-title":"Effect of exercise on the serum level and urinary excretion of tetracycline, doxycycline and sulphamethizole","volume":"12","author":"Ylitalo","year":"1977","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","first-page":"77","article-title":"Pharmacokinetic study of doxycycline in man by high performance liquid chromatography. Administration of single 200 mg doses intravenously and orally","volume":"9","author":"Fourtillan","year":"1980","journal-title":"Nouv Presse Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cpt1978242233","article-title":"Minocycline and doxycycline kinetics in chronic renal failure","volume":"24","author":"Heaney","year":"1978","journal-title":"Clin. Pharmacol Ther"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1128\/AAC.33.4.434","article-title":"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline","volume":"33","author":"Nguyen","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","first-page":"13","article-title":"The effect of dimethicone on the bioavailability of doxycycline","volume":"42","author":"Bistue","year":"1987","journal-title":"Therapie"},{"key":"ref_63","first-page":"1705","article-title":"Pharmacokinetics and bioavailability of doxycycline in humans","volume":"36","author":"Campistron","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2125.1983.tb02157.x","article-title":"The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man","volume":"16","author":"Houin","year":"1983","journal-title":"Br. J. Clin. Pharmacol"},{"key":"ref_65","first-page":"991","article-title":"Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia","volume":"35","author":"Wojcicki","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Cornely, O.A., Arenz, D., Barraud, O., Bayliss, M., Dimitriou, V., and Lovering, A.M. (2018, January 3\u20137). Phase 1 study to evaluate the safety and pharmacokinetics of single and multiple ascending doses of intravenous minocycline in healthy adult subjects [poster no. P1387]. Proceedings of the IDWeek Annual Meeting, San Francisco, CA, USA.","DOI":"10.1093\/ofid\/ofy210.1218"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cpt1973145852","article-title":"Pharmacokinetic studies on minocycline in man","volume":"14","author":"Macdonald","year":"1973","journal-title":"Clin. Pharmacol Ther"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/1.3.317","article-title":"A comparison of the bioavailability of minocycline capsules and film-coated tablets","volume":"1","author":"Cartwright","year":"1975","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Berg, J.K., Tzanis, E., Garrity-Ryan, L., Bai, S., Chitra, S., Manley, A., and Villano, S. (2018). Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02057-17"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bundrant, L.A., Tzanis, E., Garrity-Ryan, L., Bai, S., Chitra, S., Manley, A., and Villano, S. (2018). Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01487-17"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/13.1.93","article-title":"Absorption of minocycline","volume":"13","author":"Smith","year":"1984","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","unstructured":"Villano, S.J., Tzanis, E., and Tanaka, S.K. (2016, January 16\u201320). In vitro protein binding with omadacycline, a first in class aminomethylcycline antibiotic [poster no. 5180]. Proceedings of the American Society of Microbiology Microbe Annual Meeting, Boston, MA, USA."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lakota, E.A., Van Wart, S.A., Trang, M., Tzanis, E., Bhavnani, S.M., Safir, M.C., Friedrich, L., Steenbergen, J.N., Ambrose, P.G., and Rubino, C.M. (2020). Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02263-19"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jcph.814","article-title":"Effect of Food on the Bioavailability of Omadacycline in Healthy Participants","volume":"57","author":"Tzanis","year":"2017","journal-title":"J. Clin. Pharmacol"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkx039","article-title":"The complexity of minocycline serum protein binding","volume":"72","author":"Zhou","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Gotfried, M.H., Horn, K., Garrity-Ryan, L., Villano, S., Tzanis, E., Chitra, S., Manley, A., Tanaka, S.K., and Rodvold, K.A. (2017). Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01135-17"},{"key":"ref_78","first-page":"276","article-title":"Sputum and plasma doxycycline concentrations after a single oral 600 mg doxycycline dose in patients with chronic bronchitis","volume":"62","author":"Marlin","year":"1981","journal-title":"Eur. J. Respir Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1378\/chest.78.2.304","article-title":"Tissue levels of doxycycline in the human lung and pleura","volume":"78","author":"Thadepalli","year":"1980","journal-title":"Chest"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000048494","article-title":"Penetration of minocycline hydrochloride into lung tissue and sputum","volume":"47","author":"Watanabe","year":"2001","journal-title":"Chemotherapy"},{"key":"ref_81","first-page":"142","article-title":"Metabolism of minocycline in humans","volume":"10","author":"Nelis","year":"1982","journal-title":"Drug Metab. Dispos."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kovacs, S.J., Ting, L., Praestgaard, J., Sunkara, G., Sun, H., Stein, D.S., Tanaka, S.K., and Villano, S. (2020). An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01650-20"},{"key":"ref_83","unstructured":"Tanaka SK, T.E., and Villano, S. (2016, January 9\u201312). Effect of age and gender on the pharmacokinetics of oral and IV omadacycline, a new class of aminomethylcyclines [poster no. P-1318]. Proceedings of the 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00614205","article-title":"Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients","volume":"30","author":"Bocker","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF01969570","article-title":"One-dose and multiple-dose kinetics of minocycline in patients with renal disease","volume":"7","author":"Sklenar","year":"1977","journal-title":"Agents Actions"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.8.5.532","article-title":"Pharmacokinetics of minocycline in renal failure","volume":"8","author":"Welling","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/inf.1973.5.issue-3.07","article-title":"Studies on doxycycline during intravenous and oral treatment with reference to renal function","volume":"5","author":"Alestig","year":"1973","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_88","first-page":"746","article-title":"Effects of rifampicin on the pharmacokinetics of doxycycline","volume":"35","author":"Garraffo","year":"1987","journal-title":"Pathol. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"VanScoy, B.D., Lakota, E.A., Conde, H., McCauley, J., Friedrich, L., Steenbergen, J.N., Ambrose, P.G., and Bhavnani, S.M. (2020). Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02265-19"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., Marchillo, K., VanHecker, J., and Andes, D.R. (2017). In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02368-16"},{"key":"ref_91","unstructured":"Christianson, J., and Andes, D.C.W. (2001, January 25\u201328). Magnitude of the 24-h AUC\/MIC required for efficacy of doxycycline (doxy) against Streptococcus pneumoniae (SP) in a murine thigh-infection model, abstr 475. Proceedings of the 39th Infectious Diseases Society of America Annual Meeting, Infectious Disease Society of America, San Francisco, CA, USA."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003495-198700341-00015","article-title":"An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections","volume":"34","author":"Harazim","year":"1987","journal-title":"Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/22.Supplement_B.155","article-title":"Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice","volume":"22","author":"Biermann","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_94","first-page":"1014","article-title":"Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia","volume":"43","author":"Wiesner","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/39.4.499","article-title":"Atypical pneumonia in the Nordic countries: Aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group","volume":"39","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archinte.159.3.266","article-title":"Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia","volume":"159","author":"Ailani","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J. Clin. Pharm Ther"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for Community-Acquired Bacterial Pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","first-page":"194","article-title":"Clinical evaluation of intravenous minocycline","volume":"15","author":"Rogers","year":"1977","journal-title":"Int. J. Clin. Pharmacol. Biopharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.00048-13","article-title":"Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Miyashita, N., Kawai, Y., Akaike, H., Ouchi, K., Hayashi, T., Kurihara, T., Okimoto, N., and Atypical Pathogen Study Group (2012). Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-126"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","article-title":"Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients","volume":"17","author":"Kawai","year":"2012","journal-title":"Respirology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2010.06.009","article-title":"Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia","volume":"36","author":"Miyashita","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis784","article-title":"Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children","volume":"55","author":"Okada","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","first-page":"103","article-title":"Azithromycin in the treatment of pneumonias caused by Chlamydia spp.: A retrospective study","volume":"16","author":"Kuzman","year":"1996","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1111\/j.1469-0691.2011.03759.x","article-title":"Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia","volume":"18","author":"Teh","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: A systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): A phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"Cardenas","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Overcash, J.S., Bhiwandi, P., Garrity-Ryan, L., Steenbergen, J., Bai, S., Chitra, S., Manley, A., and Tzanis, E. (2019). Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02083-18"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for Acute Bacterial Skin and Skin-Structure Infections","volume":"380","author":"Green","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/cid\/cis457","article-title":"Does doxycycline protect against development of Clostridium difficile infection?","volume":"55","author":"Doernberg","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1469-0691.2009.03048.x","article-title":"In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993\u20132007 in Sweden","volume":"16","author":"Noren","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kim O, L.R., and Traczewski, M. (2020, March 24). Activity and Efficacy of Omadacycline against Clostridium Difficile. ECCMID 2016, Poster P1325. Available online: https:\/\/paratekpharma.com\/media\/1250\/kim-activity-and-efficacy-of-omadacycline-against-clostridium-difficile.pdf.","DOI":"10.26226\/morressier.56d6be7ad462b80296c97dee"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archinte.1997.00440340035003","article-title":"Doxycycline revisited","volume":"157","author":"Joshi","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lodise, T.P., Van Le, H., and LaPensee, K. (2020). Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals. Antibiotics, 9.","DOI":"10.3390\/antibiotics9090577"},{"key":"ref_119","unstructured":"(2020, August 01). Study to Evaluate the PK of PO Omadacycline in Adults with Community-Acquired Bacterial Pneumonia, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04160260."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.cmi.2015.07.007","article-title":"Minocycline activity against clinical isolates of multidrug-resistant Acinetobacter baumannii","volume":"21","author":"Adibhesami","year":"2015","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/12\/905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:44Z","timestamp":1760179484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/12\/905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":120,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["antibiotics9120905"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9120905","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]}}}